Abstract
Bcl-2 is an anti-apoptotic oncoprotein and its protein levels are inversely correlated with prognosis in many cancers. However, the role of Bcl-2 in the progression of prostate cancer is not clear. Here we report that Bcl-2 is required for the progression of LNCaP prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. The mRNA and protein levels of Bcl-2 are significantly increased in androgen-independent prostate cancer cells. shRNA-mediated gene silencing of Bcl-2 in androgen-independent prostate cancer cells promotes UV-induced apoptosis and suppresses the growth of prostate tumors in vivo. Growing androgen-dependent cells under androgen-deprivation conditions results in formation of androgen-independent colonies; and the transition from androgen-dependent to androgen-independent growth is blocked by ectopic expression of the Bcl-2 antagonist Bax or Bcl-2 shRNA. Thus, our results demonstrate that Bcl-2 is not only critical for the survival of androgen-independent prostate cancer cells, but is also required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Huggins C, Hodges CV . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 1941; 168:9–12.
Miyamoto H, Messing EM, Chang C . Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61:332–353.
Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A . Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999; 54:36–46.
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML . Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52:6940–6944.
Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143:390–400.
Kokontis JM, Hay N, Liao S . Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12:941–953.
van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH, The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 1991; 40:207–214.
Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW . Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57:406–412.
Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, Foury O, Morel Y, Andre JG . Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 1995; 55:67–76.
Kokontis JM, Hsu S, Chuu CP, et al. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate. 2005; 65:287–298.
Waller AS, Sharrard RM, Berthon P, Maitland NJ . Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. J Mol Endocrinol 2000; 24:339–351.
Xiang J, Chao DT, Korsmeyer SJ . BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A 1996; 93:14559–14563.
Fukuchi J, Hiipakka RA, Kokontis JM, et al. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 2004; 64:7682–7685.
Chang BD, Roninson IB . Inducible retroviral vectors regulated by lac repressor in mammalian cells. Gene 1996; 183:137–142.
Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP . Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 1991; 51:3814–3817.
Kokontis J, Takakura K, Hay N, Liao S . Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54:1566–1573.
Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L . Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 2002; 60:52–56; discussion 56.
Catz SD, Johnson JL . BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29–37.
Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN . Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993; 4:327–332.
Korsmeyer SJ Bcl-2: an antidote to programmed cell death. Cancer Surv 1992; 15:105–118.
Knudson CM, Korsmeyer SJ . Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997; 16:358–363.
Denmeade SR, Lin XS, Isaacs JT . Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28:251–265.
Acknowledgements
This work was partially supported by NIH K01 award CA090516 and the Funding from Illinois Institute of Technology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, Y., Fukuchi, J., Hiipakka, R. et al. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 17, 531–536 (2007). https://doi.org/10.1038/cr.2007.12
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/cr.2007.12
Keywords
This article is cited by
-
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Journal of Hematology & Oncology (2022)
-
Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference
Journal of Biomedical Science (2022)
-
Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells
Cellular and Molecular Life Sciences (2020)
-
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-XL cell survival genes
BMC Cancer (2018)
-
A common effect of angiotensin II and relaxin 2 on the PNT1A normal prostate epithelial cell line
Journal of Physiology and Biochemistry (2016)
